Literature DB >> 25026212

Hematogenous metastasis of ovarian cancer: rethinking mode of spread.

Sunila Pradeep1, Seung W Kim2, Sherry Y Wu1, Masato Nishimura1, Pradeep Chaluvally-Raghavan3, Takahito Miyake1, Chad V Pecot4, Sun-Jin Kim2, Hyun Jin Choi1, Farideh Z Bischoff5, Julie Ann Mayer5, Li Huang2, Alpa M Nick1, Carolyn S Hall6, Cristian Rodriguez-Aguayo7, Behrouz Zand1, Heather J Dalton1, Thiruvengadam Arumugam2, Ho Jeong Lee2, Hee Dong Han8, Min Soon Cho9, Rajesha Rupaimoole1, Lingegowda S Mangala10, Vasudha Sehgal3, Sang Cheul Oh11, Jinsong Liu12, Ju-Seog Lee3, Robert L Coleman1, Prahlad Ram3, Gabriel Lopez-Berestein7, Isaiah J Fidler2, Anil K Sood13.   

Abstract

Ovarian cancer has a clear predilection for metastasis to the omentum, but the underlying mechanisms involved in ovarian cancer spread are not well understood. Here, we used a parabiosis model that demonstrates preferential hematogenous metastasis of ovarian cancer to the omentum. Our studies revealed that the ErbB3-neuregulin 1 (NRG1) axis is a dominant pathway responsible for hematogenous omental metastasis. Elevated levels of ErbB3 in ovarian cancer cells and NRG1 in the omentum allowed for tumor cell localization and growth in the omentum. Depletion of ErbB3 in ovarian cancer impaired omental metastasis. Our results highlight hematogenous metastasis as an important mode of ovarian cancer metastasis. These findings have implications for designing alternative strategies aimed at preventing and treating ovarian cancer metastasis.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25026212      PMCID： PMC4100212          DOI： 10.1016/j.ccr.2014.05.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  33 in total

1.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Authors:  Michael S Gordon; Daniela Matei; Carol Aghajanian; Ursula A Matulonis; Molly Brewer; Gini F Fleming; John D Hainsworth; Agustin A Garcia; Mark D Pegram; Russell J Schilder; David E Cohn; Lynda Roman; Mika K Derynck; Kimmie Ng; Benjamin Lyons; David E Allison; David A Eberhard; Thinh Q Pham; Randall C Dere; Beth Y Karlan
Journal:  J Clin Oncol       Date:  2006-08-08       Impact factor: 44.544

2.  A phase 3 trial of bevacizumab in ovarian cancer.

Authors:  Timothy J Perren; Ann Marie Swart; Jacobus Pfisterer; Jonathan A Ledermann; Eric Pujade-Lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Christian Kurzeder; Andreas du Bois; Jalid Sehouli; Rainer Kimmig; Anne Stähle; Fiona Collinson; Sharadah Essapen; Charlie Gourley; Alain Lortholary; Frédéric Selle; Mansoor R Mirza; Arto Leminen; Marie Plante; Dan Stark; Wendi Qian; Mahesh K B Parmar; Amit M Oza
Journal:  N Engl J Med       Date:  2011-12-29       Impact factor: 91.245

3.  Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.

Authors:  R A Burger
Journal:  Ann Oncol       Date:  2011-12       Impact factor: 32.976

4.  SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.

Authors:  Ahmed Ashour Ahmed; Zhen Lu; Nicholas B Jennings; Dariush Etemadmoghadam; Luisa Capalbo; Rodrigo O Jacamo; Nuno Barbosa-Morais; Xiao-Feng Le; Pablo Vivas-Mejia; Gabriel Lopez-Berestein; Geoffrey Grandjean; Geoffrey Bartholomeusz; Warren Liao; Michael Andreeff; David Bowtell; David M Glover; Anil K Sood; Robert C Bast
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

5.  Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.

Authors:  Sun Joo Lee; Sukhen C Ghosh; Hee Dong Han; Rebecca L Stone; Justin Bottsford-Miller; De Yue Shen; Edmond J Auzenne; Alejandro Lopez-Araujo; Chunhua Lu; Masato Nishimura; Chad V Pecot; Behrouz Zand; Duangmani Thanapprapasr; Nicholas B Jennings; Yu Kang; Jie Huang; Wei Hu; Jim Klostergaard; Anil K Sood
Journal:  Clin Cancer Res       Date:  2012-06-12       Impact factor: 12.531

6.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

7.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

8.  Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts.

Authors:  D Tarin; J E Price; M G Kettlewell; R G Souter; A C Vass; B Crossley
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

9.  Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines.

Authors:  Sachin M Apte; Corazon D Bucana; Jerald J Killion; David M Gershenson; Isaiah J Fidler
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

10.  Use of data-biased random walks on graphs for the retrieval of context-specific networks from genomic data.

Authors:  Kakajan Komurov; Michael A White; Prahlad T Ram
Journal:  PLoS Comput Biol       Date:  2010-08-19       Impact factor: 4.475
View more
  124 in total

1.  Erythropoietin Stimulates Tumor Growth via EphB4.

Authors:  Sunila Pradeep; Jie Huang; Edna M Mora; Alpa M Nick; Min Soon Cho; Sherry Y Wu; Kyunghee Noh; Chad V Pecot; Rajesha Rupaimoole; Martin A Stein; Stephan Brock; Yunfei Wen; Chiyi Xiong; Kshipra Gharpure; Jean M Hansen; Archana S Nagaraja; Rebecca A Previs; Pablo Vivas-Mejia; Hee Dong Han; Wei Hu; Lingegowda S Mangala; Behrouz Zand; Loren J Stagg; John E Ladbury; Bulent Ozpolat; S Neslihan Alpay; Masato Nishimura; Rebecca L Stone; Koji Matsuo; Guillermo N Armaiz-Peña; Heather J Dalton; Christopher Danes; Blake Goodman; Cristian Rodriguez-Aguayo; Carola Kruger; Armin Schneider; Shyon Haghpeykar; Padmavathi Jaladurgam; Mien-Chie Hung; Robert L Coleman; Jinsong Liu; Chun Li; Diana Urbauer; Gabriel Lopez-Berestein; David B Jackson; Anil K Sood
Journal:  Cancer Cell       Date:  2015-10-17       Impact factor: 31.743

2.  MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.

Authors:  Yunqi Lu; Zhongyi Hu; Lingegowda S Mangala; Zachary E Stine; Xiaowen Hu; Dahai Jiang; Yan Xiang; Youyou Zhang; Sunila Pradeep; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Angelo M DeMarzo; Anil K Sood; Lin Zhang; Chi V Dang
Journal:  Cancer Res       Date:  2017-11-27       Impact factor: 12.701

Review 3.  The biological significance and clinical applications of exosomes in ovarian cancer.

Authors:  Kalpana Deepa Priya Dorayappan; John J Wallbillich; David E Cohn; Karuppaiyah Selvendiran
Journal:  Gynecol Oncol       Date:  2016-04-10       Impact factor: 5.482

4.  Host CYP27A1 expression is essential for ovarian cancer progression.

Authors:  Sisi He; Liqian Ma; Amy E Baek; Anna Vardanyan; Varsha Vembar; Joy J Chen; Adam T Nelson; Joanna E Burdette; Erik R Nelson
Journal:  Endocr Relat Cancer       Date:  2019-07       Impact factor: 5.678

Review 5.  Systems Biology of Cancer Metastasis.

Authors:  Yasir Suhail; Margo P Cain; Kiran Vanaja; Paul A Kurywchak; Andre Levchenko; Raghu Kalluri
Journal:  Cell Syst       Date:  2019-08-28       Impact factor: 10.304

6.  Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.

Authors:  Majid Momeny; Reza Ghasemi; Giovanni Valenti; Mariska Miranda; Ali Zekri; Ghazaleh Zarrinrad; Sepehr Javadikooshesh; Marjan Yaghmaie; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Seyed H Ghaffari
Journal:  Tumour Biol       Date:  2015-10-19

7.  New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination.

Authors:  Lan G Coffman; Daniela Burgos-Ojeda; Rong Wu; Kathleen Cho; Shoumei Bai; Ronald J Buckanovich
Journal:  Transl Res       Date:  2016-03-30       Impact factor: 7.012

8.  Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Authors:  Monika Haemmerle; Morgan L Taylor; Tony Gutschner; Sunila Pradeep; Min Soon Cho; Jianting Sheng; Yasmin M Lyons; Archana S Nagaraja; Robert L Dood; Yunfei Wen; Lingegowda S Mangala; Jean M Hansen; Rajesha Rupaimoole; Kshipra M Gharpure; Cristian Rodriguez-Aguayo; Sun Young Yim; Ju-Seog Lee; Cristina Ivan; Wei Hu; Gabriel Lopez-Berestein; Stephen T Wong; Beth Y Karlan; Douglas A Levine; Jinsong Liu; Vahid Afshar-Kharghan; Anil K Sood
Journal:  Nat Commun       Date:  2017-08-21       Impact factor: 14.919

9.  Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.

Authors:  Deepak Parashar; Bindu Nair; Anjali Geethadevi; Jasmine George; Ajay Nair; Shirng-Wern Tsaih; Ishaque P Kadamberi; Gopa Kumar Gopinadhan Nair; Yiling Lu; Ramani Ramchandran; Denise S Uyar; Janet S Rader; Prahlad T Ram; Gordon B Mills; Sunila Pradeep; Pradeep Chaluvally-Raghavan
Journal:  Cancer Res       Date:  2020-10-21       Impact factor: 12.701

Review 10.  Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kay-Pong Yip; Chi Lam Au Yeung; Stephen T C Wong; Samuel C Mok
Journal:  Am J Physiol Cell Physiol       Date:  2015-07-29       Impact factor: 4.249
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.